Former CEO Anne Wojcicki prevails in 23andMe auction, with final $305M bid

Anne Wojcicki's TTAM Research Institute won the bankruptcy auction for 23andMe with a $305 million bid, surpassing Regeneron's $256 million offer and retaining control of the consumer genetics company. The deal, pending court approval, ensures 23andMe's consumer genome services and privacy policies will remain unchanged, with TTAM committing to enhanced data safeguards and honoring existing user data deletion options. This outcome follows Wojcicki's efforts to reopen bidding with backing from an unnamed Fortune 500 company, marking a significant increase from her prior $74 million privatization offer and providing greater value to stakeholders.

Analysis

Anne Wojcicki's TTAM Research Institute has successfully secured 23andMe in a bankruptcy auction with a $305 million bid, notably surpassing Regeneron's $256 million offer and a significantly lower $74 million proposal from Wojcicki herself last summer. This acquisition, pending final court approval on June 17, ensures the continuity of 23andMe's consumer genome services and its existing privacy policies, with TTAM committing to enhanced data safeguards—a crucial point given public concerns following the Chapter 11 filing in March. The deal, facilitated by financial support from an undisclosed Fortune 500 company, mandates that any future owner must also adhere to these privacy commitments, including user data deletion rights and research opt-out provisions. This outcome delivers "significantly more value to stakeholders," according to 23andMe's board chair, especially considering the company's stock value had plummeted over 97% since its 2021 IPO, and marks a transition for 23andMe into a nonprofit entity under its former CEO's leadership.

Key Decisions for Investors

• For 23andMe stakeholders, the $305 million acquisition price represents a substantially improved recovery from the bankruptcy proceedings compared to earlier valuations, although the transition to a non-profit structure under TTAM changes the future financial profile of the entity.
• Investors in Regeneron (REGN) should recognize that its bid to integrate 23andMe's genetic data into its R&D pipeline was unsuccessful, potentially requiring REGN to explore alternative data acquisition strategies or partnerships.
• The transaction highlights the persistent strategic value attributed to large-scale genetic databases and robust data privacy frameworks, even in distressed M&A scenarios, and indicates continued institutional interest in the genomics sector, as evidenced by the backing from a Fortune 500 company.